Kei Muro, MD, Aichi Cancer Center Hospital

home / authors / kei-muro-md-aichi-cancer-center-hospital

Articles

Metastatic Gastric Cancer: Recent Advances and Future Directions

Metastatic Gastric Cancer: Recent Advances and Future Directions

Salah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center;Daniel V. Catenacci, MD, University of Chicago;David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center;Kei Muro, MD, Aichi Cancer Center Hospital
June 2nd 2020

Read More

Perioperative Strategies in Metastatic Gastric Cancer

Perioperative Strategies in Metastatic Gastric Cancer

Salah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center;Daniel V. Catenacci, MD, University of Chicago;David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center;Kei Muro, MD, Aichi Cancer Center Hospital
June 2nd 2020

Read More

Metastatic Gastric Cancer: Promising Later-Line Trials

Metastatic Gastric Cancer: Promising Later-Line Trials

Salah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center;Daniel V. Catenacci, MD, University of Chicago;David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center;Kei Muro, MD, Aichi Cancer Center Hospital
June 2nd 2020

Read More

Metastatic Gastric Cancer: Promising Second-Line Trials

Metastatic Gastric Cancer: Promising Second-Line Trials

Salah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center;Daniel V. Catenacci, MD, University of Chicago;David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center;Kei Muro, MD, Aichi Cancer Center Hospital
June 2nd 2020

Read More

Metastatic Gastric Cancer: Novel Agents Targeting FGF

Metastatic Gastric Cancer: Novel Agents Targeting FGF

Salah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center;Daniel V. Catenacci, MD, University of Chicago;David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center;Kei Muro, MD, Aichi Cancer Center Hospital
June 2nd 2020

Read More

Gastric Cancer: Frontline Checkpoint Inhibitor Trials

Gastric Cancer: Frontline Checkpoint Inhibitor Trials

Salah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center;Daniel V. Catenacci, MD, University of Chicago;David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center;Kei Muro, MD, Aichi Cancer Center Hospital
June 2nd 2020

Read More

Metastatic Gastric Cancer: Promising Frontline Trials

Metastatic Gastric Cancer: Promising Frontline Trials

Salah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center;Daniel V. Catenacci, MD, University of Chicago;David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center;Kei Muro, MD, Aichi Cancer Center Hospital
June 2nd 2020

Read More

Emerging Biomarkers in Metastatic Gastric Cancer

Emerging Biomarkers in Metastatic Gastric Cancer

Salah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center;Daniel V. Catenacci, MD, University of Chicago;David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center;Kei Muro, MD, Aichi Cancer Center Hospital
June 2nd 2020

Read More

Later Lines of Therapy in Metastatic Gastric Cancer

Later Lines of Therapy in Metastatic Gastric Cancer

Salah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center;Daniel V. Catenacci, MD, University of Chicago;David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center;Kei Muro, MD, Aichi Cancer Center Hospital
June 2nd 2020

Read More

Chemotherapy + Ramucirumab as Second-Line Therapy in mGC

Chemotherapy + Ramucirumab as Second-Line Therapy in mGC

Salah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center;Daniel V. Catenacci, MD, University of Chicago;David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center;Kei Muro, MD, Aichi Cancer Center Hospital
June 2nd 2020

Read More

Global Use of Second-Line Therapy in mGC

Global Use of Second-Line Therapy in mGC

Salah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center;Daniel V. Catenacci, MD, University of Chicago;David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center;Kei Muro, MD, Aichi Cancer Center Hospital
June 2nd 2020

Read More

Metastatic Gastric Cancer: Identifying Disease Progression

Metastatic Gastric Cancer: Identifying Disease Progression

Salah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center;Daniel V. Catenacci, MD, University of Chicago;David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center;Kei Muro, MD, Aichi Cancer Center Hospital
June 2nd 2020

Read More

Switch Maintenance in Gastric Cancer: Results of JAVELIN Gastric 100

Switch Maintenance in Gastric Cancer: Results of JAVELIN Gastric 100

Salah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center;Daniel V. Catenacci, MD, University of Chicago;David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center;Kei Muro, MD, Aichi Cancer Center Hospital
June 2nd 2020

Read More

Gastric Cancer: Global Perspectives on Maintenance Therapy

Gastric Cancer: Global Perspectives on Maintenance Therapy

Salah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center;Daniel V. Catenacci, MD, University of Chicago;David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center;Kei Muro, MD, Aichi Cancer Center Hospital
June 2nd 2020

Read More

Is Frontline IO Therapy Appropriate in Gastric Cancer?

Is Frontline IO Therapy Appropriate in Gastric Cancer?

Salah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center;Daniel V. Catenacci, MD, University of Chicago;David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center;Kei Muro, MD, Aichi Cancer Center Hospital
June 2nd 2020

Read More

Metastatic Gastric Cancer: Factors in Selecting Frontline Therapy

Metastatic Gastric Cancer: Factors in Selecting Frontline Therapy

Salah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center;Daniel V. Catenacci, MD, University of Chicago;David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center;Kei Muro, MD, Aichi Cancer Center Hospital
June 2nd 2020

Read More

Global Use of Frontline Therapy in Metastatic Gastric Cancer

Global Use of Frontline Therapy in Metastatic Gastric Cancer

Salah-Eddin Al-Batran, MD, Krankenhaus Nordwest-University Cancer Center;Daniel V. Catenacci, MD, University of Chicago;David Ilson, MD, PhD, Memorial Sloan Kettering Cancer Center;Kei Muro, MD, Aichi Cancer Center Hospital
June 2nd 2020

Read More

Latest Updated Articles

Sarwish Rafiq, PhD
Published: July 9th 2024 | Updated: July 10th 2024
Dr Rafiq on Novel Strategies for CAR T-Cell Engineering in Solid Tumors
Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Julia Rotow, MD, clinical director, Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute; assistant professor, medicine, Harvard Medical School
Published: July 25th 2024 | Updated: July 27th 2024
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Joshua K. Sabari, MD, assistant professor, Department of Medicine, New York University Grossman School of Medicine; director, High Reliability Organization Initiatives, Perlmutter Cancer Center
Published: July 25th 2024 | Updated: July 27th 2024
Dr Sabari on Barriers to Biomarker Testing in NSCLC
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL
5 KOLs are featured in this series.
Published: July 18th 2024 | Updated: July 27th 2024
Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data